<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04388124</url>
  </required_header>
  <id_info>
    <org_study_id>2018/350/HP</org_study_id>
    <nct_id>NCT04388124</nct_id>
  </id_info>
  <brief_title>VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION</brief_title>
  <acronym>ENDOTHELIN-2</acronym>
  <official_title>VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The management of patients with resistant arterial hypertension, who are characterized by a&#xD;
      very high cardiovascular risk, remains a major therapeutic issue. The use of endothelin-1&#xD;
      (ET-1) receptor antagonists, in addition to lowering blood pressure, may also improve&#xD;
      endothelial function in these patients. The objective of this study is to assess the vascular&#xD;
      impact of an ET-1 receptor antagonist on vascular function and systemic and central&#xD;
      hemodynamics in patients with resistant arterial hypertension and ensure their good renal&#xD;
      tolerance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Modification of the pharmaceutical form, removal from the primary packaging and repackaging-&gt; tablet of Bosentan will be encapsuled. The pharmaceutical form of placebo and bosentant will be identical</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>assess the effect of ET-1 receptor antagonist administration during 8 weeks on endothelial function in patients with resistant hypertension.</measure>
    <time_frame>through study completion, an average of 22 months</time_frame>
    <description>8-week change in amplitude of endothelium-dependent radial artery dilatation with sustained increase in blood flow</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>assess the effect of the administration of an ET-1 receptor antagonist during 8 weeks on systemic and central hemodynamics</measure>
    <time_frame>through study completion, an average of 22 months</time_frame>
    <description>8 week change in peripheral and central arterial pressures and arterial stiffness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess the effect of the administration of an ET-1 receptor antagonist during 8 weeks on local concentrations of endothelial factors during a sustained increase of the blood flow</measure>
    <time_frame>through study completion, an average of 22 months</time_frame>
    <description>8-week change in local concentrations of NO, EETs and ET-1 with sustained increase in blood flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess the effect of the administration of an ET-1 receptor antagonist during 8 weeks on the renal function of patients with resistant hypertension.</measure>
    <time_frame>through study completion, an average of 22 months</time_frame>
    <description>Variation in 8 weeks of natriuresis and measured glomerular filtration rate (DTPA labeled by the technetium 99m)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Resistant Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient will receive placebo for 56 days: 2 capsules of 62.5 mg per day for 27 days +/-1 day, 2 capsules of 125 mg per day for 27 days +/-1 day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bosentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will receive Bosentan for 56 days: 2 capsules of 62.5 mg per day for 27 days +/-1 day, 2 capsules of 125 mg per day for 27 days +/-1 day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosentan</intervention_name>
    <description>vascular assesment Clinical exam urinary analysis blood results natriuresis and measured glomerular filtration rate</description>
    <arm_group_label>Bosentan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age between 30 and 80 years old&#xD;
&#xD;
          -  Patients with resistant hypertension defined according to the criteria recognized by&#xD;
             the French Society of Hypertension (SFHTA): arterial pressure greater than or equal to&#xD;
             140 and / 90 mm Hg under triple antihypertensive therapy at optimal dose comprising at&#xD;
             least one diuretic pendant at less than 4 weeks.&#xD;
&#xD;
          -  Patients with resistant hypertension confirmed by self-measurement (≥135 / 85 mmHg on&#xD;
             average) or by ambulatory blood pressure measurement (mean of 24h ≥130 / 80 mmHg).&#xD;
&#xD;
          -  Hemoglobin level ≥ 12 g / dL&#xD;
&#xD;
          -  For women of childbearing potential, reliable methods of contraception (as defined by&#xD;
             the WHO-Pearl Index) should be used (hormonal contraception should not be the only&#xD;
             contraceptive method used during bosentan treatment).&#xD;
&#xD;
          -  For postmenopausal women: confirmatory diagnosis (non-medically induced amenorrhea for&#xD;
             at least 12 months and age greater than 45, before the inclusion visit)&#xD;
&#xD;
          -  Patient who read and understood the newsletter and signed the consent form&#xD;
&#xD;
          -  Patient affiliated to a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with hypertension&#xD;
&#xD;
          -  Patients with secondary arterial hypertension other than sleep apnea syndrome or&#xD;
             chronic renal failure stage 2 or 3.&#xD;
&#xD;
          -  Patients with hypertension greater than or equal to 180 and / or 110mmHg&#xD;
&#xD;
          -  Chronic renal failure stage 4 and 5 (defined by DFG CKD-EPI &lt;30 ml / min / 1,73m²)&#xD;
&#xD;
          -  Renal transplant patient XML File Identifier: CEyMau8sPo+QFyOLD1ZEY3ZGFow= Page 11/22&#xD;
&#xD;
          -  Orthostatic hypotension (decreased SBP&gt; 20mmHg and / or DBP&gt; 10mmHg occurring within 3&#xD;
             minutes of standing).&#xD;
&#xD;
          -  Contra-indication to NATISPRAY 0.30 mg / dose, oral spray solution (including nitrate&#xD;
             hypersensitivity) in accordance with the NATISPRAY&#xD;
&#xD;
        SPC:&#xD;
&#xD;
          -  shock, severe hypotension,&#xD;
&#xD;
          -  in combination with sildenafil&#xD;
&#xD;
          -  obstructive cardiomyopathy,&#xD;
&#xD;
          -  inferior court inferior myocardial infarction with right ventricular extension, except&#xD;
             in case of evidence of left ventricular failure,&#xD;
&#xD;
          -  intracranial hypertension,&#xD;
&#xD;
             • Contra-indication to BOSENTAN MYLAN 62.5 mg and 125 mg filmcoated tablets:&#xD;
&#xD;
          -  Hypersensitivity to the active substance or to any of the excipients listed in the SPC&#xD;
             Moderate to severe hepatic insufficiency corresponding to class B or C of the&#xD;
             Child-Pugh classification&#xD;
&#xD;
          -  Serum levels of liver aminotransferases, ASAT and / or ALAT&gt; 3 times the upper limit&#xD;
             of normal at start of treatment (results less than 3 months old).&#xD;
&#xD;
          -  Association with ciclosporin A&#xD;
&#xD;
               -  Known allergy to cellulose&#xD;
&#xD;
               -  Patients treated with: tacrolimus or sirolimus, fluconazole or other CYP2C9 or&#xD;
                  CYP3A4 inhibitors, glibenclamide, rifampicin, antiretroviral drugs including&#xD;
                  lopinavir + ritonavir, warfarin, simvastatin, ketoconazole, epoprostenol,&#xD;
                  sildenafil and digoxin&#xD;
&#xD;
               -  Pregnant, breastfeeding woman, or woman of childbearing potential not using&#xD;
                  reliable methods of contraception (hormonal contraception should not be the only&#xD;
                  contraceptive method used during bosentan treatment) or no proven reliable&#xD;
                  effective contraception;&#xD;
&#xD;
               -  Person deprived of liberty by an administrative or judicial decision or person&#xD;
                  placed under the protection of justice, under tutorship or curatorship&#xD;
&#xD;
               -  Patient participating or having participated in the 4 weeks prior to inclusion in&#xD;
                  a clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endothelin-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

